In patients with Ph+ CML-CP Routine testing tells you more Ph+ CML, Philadelphia chromosome–positive chronic myeloid leukemia; CP, chronic phase;
RQ-PCR, real-time quantitative polymerase chain reaction; IS, International Scale.
In patients monitored 3 to 4 times per year 91% reduction in the risk of progression1 The hazard of disease progression was 91% lower for patients in the group that received 3 to 4 RQ-PCR tests
per year compared with the group that received 0 RQ-PCR tests per year (HR=0.09, 95% CI: 0.02-0.38, P=.001).1
Visit
www.MonitorCML.com
to learn more
Find out if your patients are reaching molecular
milestones with IS RQ-PCR testing Reference: 1. Goldberg SL, Chen L, Guerin A, et al. Curr Med Res Opin. 2013;29(9):1075-1082. © 2015 Novartis             9/15             CDE-1124074